Innate Pharma SA
Innate Pharma SA (IPHYF): 4 pipeline candidates · 4 clinical trials. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Innate Pharma SAacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$154.9M
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Innate Pharma SA's pipeline?
Innate Pharma SA (IPHYF) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Innate Pharma SA's lead drug candidate?
Innate Pharma SA's most advanced tracked candidate is iph2101 (Phase 2) for Smoldering Multiple Myeloma.
What is Innate Pharma SA's market capitalization?
Innate Pharma SA's market capitalization is approximately $154.9M.
Who is the CEO of Innate Pharma SA?
Mr. Jonathan E. Dickinson B.Sc., M.B.A. is the chief executive officer of Innate Pharma SA (IPHYF).
Get the full picture on Innate Pharma SA
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.